视网膜损伤/保护中的激肽释放酶系统。

The kallikrein system in retinal damage/protection.

作者信息

Masuda Tomomi, Shimazawa Masamitsu, Hara Hideaki

机构信息

Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, Japan.

出版信息

Eur J Pharmacol. 2015 Feb 15;749:161-3. doi: 10.1016/j.ejphar.2014.10.007. Epub 2014 Oct 18.

DOI:10.1016/j.ejphar.2014.10.007

PMID:25448306

Abstract

Kallikrein is a serine protease involved in the kallikrein-kinnin system. Kallikrein is derived from the blood plasma or tissue, and is correlated with aggravation and improvement in eye diseases, such as, glaucoma, diabetic retinopathy, age-related macular degeneration, and ocular ischemic syndrome. The plasma kallikrein stimulates retinal vascular permeability and intraocular hemorrhage. On the other hand, we had reported that the tissue kallikrein normalizes retinal vasopermeability and inhibited retinal neovascularization and retinal ischemic injury. The protective mechanisms of the tissue-derived kallikrein include the cleavage of vascular endothelial growth factor (VEGF), which suggests that the tissue kallikrein could be potentially-effective against any disease involving the VEGF production.

摘要

激肽释放酶是一种参与激肽释放酶-激肽系统的丝氨酸蛋白酶。激肽释放酶源自血浆或组织，与眼部疾病如青光眼、糖尿病视网膜病变、年龄相关性黄斑变性和眼部缺血综合征的加重与改善相关。血浆激肽释放酶会刺激视网膜血管通透性和眼内出血。另一方面，我们曾报道组织激肽释放酶可使视网膜血管通透性恢复正常，并抑制视网膜新生血管形成和视网膜缺血性损伤。组织源性激肽释放酶的保护机制包括对血管内皮生长因子（VEGF）的裂解，这表明组织激肽释放酶可能对任何涉及VEGF产生的疾病具有潜在疗效。